Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

Cell Death and Disease

Volumn 3, Issue 12, 2012, Pages

  Fokas, E ^a,c   Prevo, R ^a   Pollard, J R ^b   Reaper, P M ^b   Charlton, P A ^b   Cornelissen, B ^a   Vallis, K A ^a   Hammond, E M ^a   Olcina, M M ^a   Gillies McKenna, W ^a   Musche, R J ^a   Brunner, T B ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ATR; novel inhibitor; pancreatic cancer; radiosensitiser; tumor selectivity

Indexed keywords

ANTINEOPLASTIC AGENT; ATR PROTEIN; CHECKPOINT KINASE 1; GEMCITABINE; HISTONE H2AX; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAD51 PROTEIN; UNCLASSIFIED DRUG; VE 822;

ABDOMINAL RADIOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; RECOMBINATION REPAIR; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

MURINAE;

EID: 84871237979     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.181     Document Type: Article

References (49)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
2. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708.
3. Ben-Josef E, Lawrence TS. Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 2012; 9: 9-10.
4. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist 2012; 17: 192-200.
5. Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 2010; 5: 64.
6. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172.
7. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
8. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204.
9. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11: 239-253.
10. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
11. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
12. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 2011; 98: 1041-1055.
13. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-329.
14. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011; 10: 351-364.
15. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA et al. Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7: 428-430.
16. Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, Brown EJ. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet 2009; 41: 1144-1149.
17. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierre A et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8: 1196-1205.
18. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011; 18: 721-727.
19. Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 2009; 41: 891-898.
20. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 2011; 30: 2526-2533.
21. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 2001; 98: 9092-9097.
22. Nghiem P, Park PK, Kim YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002; 277: 4428-4434.
23. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18: 1331-1335.
24. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70: 9693-9702.
25. Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 2012; 122: 241-252.
26. Hammond EM, Giaccia AJ. The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst) 2004; 3: 1117-1122.
27. Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer 2012; 107: 291-299.
28. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 2012; 13: 1072-1081.
29. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 2011 54: 2320-2330.
30. Charrier J-D, Durrant S, Kay D, Knegtel R, MacCormick S, Mortimore M et al. Pyrazine derivatives useful as inhibitors of ATR kinase and their preparation and use in the treatment of diseases. 2010; WO 2010071837 A1 20100624.
31. Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004; 10: 5447-5454.
32. Potten CS, Merritt A, Hickman J, Hall P, Faranda A. Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int J Radiat Biol 1994; 65: 71-78.
33. Trier JS, Browning TH. Morphologic response of the mucosa of human small intestine to X-ray exposure. J Clin Invest 1966; 45: 194-204.
34. Cornelissen B, Kersemans V, Darbar S, Thompson J, Shah K, Sleeth K et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res 2011; 71: 4539-4549.
35. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17: 402-412.
36. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008; 133: 864-877.
37. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth MATR. and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 2009; 5: e1000324.
38. Frankenberg-Schwager M, Gebauer A, Koppe C, Wolf H, Pralle E, Frankenberg D. Singlestrand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation. Radiat Res 2009; 171: 265-273.
39. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998; 26: 2859-2864.
40. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
41. Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 2011; 122: 241-252.
42. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated-and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007; 6: 1406-1413.
43. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 2011; 30: 2526-2533.
44. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011; 105: 372-381.
45. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005; 65: 8433-8441.
46. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008; 68: 5915-5923.
47. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/Mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 2012; 7: 48.
48. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
49. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012; 72: 239-248.